| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
| Exact Mass |
540.242
|
|---|---|
| CAS # |
125995-03-1
|
| Related CAS # |
Atorvastatin lactone-d5
|
| PubChem CID |
6483036
|
| Appearance |
White to light yellow solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
674.8±55.0 °C at 760 mmHg
|
| Melting Point |
103-106ºC
|
| Flash Point |
361.9±31.5 °C
|
| Vapour Pressure |
0.0±2.2 mmHg at 25°C
|
| Index of Refraction |
1.617
|
| LogP |
4.3
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
40
|
| Complexity |
834
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
O=C(C1=C(C(C)C)N(CC[C@@H]2C[C@@H](O)CC(O2)=O)C(C3=CC=C(F)C=C3)=C1C4=CC=CC=C4)NC5=CC=CC=C5
|
| InChi Key |
OUCSEDFVYPBLLF-KAYWLYCHSA-N
|
| InChi Code |
InChI=1S/C33H33FN2O4/c1-21(2)31-30(33(39)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-27-19-26(37)20-28(38)40-27/h3-16,21,26-27,37H,17-20H2,1-2H3,(H,35,39)/t26-,27-/m1/s1
|
| Chemical Name |
5-(4-fluorophenyl)-1-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-N,4-diphenyl-2-propan-2-ylpyrrole-3-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~46.24 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.62 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT00414531 | COMPLETED | Drug: Atorvastatin | Myotoxicity of Atorvastatin Treatment | University of Oslo School of Pharmacy | 2005-05 | Phase 4 |
| NCT03604471 | COMPLETED | Drug: Atorvastatin | Hypercholesterolemia | Université Catholique de Louvain | 2017-08-08 | Phase 4 |
| NCT03311841 | COMPLETEDWITH RESULTS | Drug: Midazolam oral solution Drug: Dabigatran and pitavastatin oral solution Drug: Atorvastatin and rosuvastatin oral solution Drug: Rifampin |
Renal Insufficiency | Merck Sharp & Dohme LLC | 2018-03-01 | Phase 1 |
| NCT05334108 | COMPLETED | Drug: Ecopipam Combination Product: Cohort 1 Probe Substrate Cocktail Drug: Cohort 2 Probe Substrate Combination Product: Cohort 3 Probe Substrate Cocktail |
Drug Interaction | Emalex Biosciences Inc. | 2022-04-26 | Phase 1 |
| NCT04764851 | TERMINATED | Drug: ecopipam HCl ~2mg/kg/day Combination Product: Cohort 1 Probe Cocktail Combination Product: Cohort 2 Probe Cocktail Combination Product: Cohort 3 Probe Cocktail |
Drug-Interactions | Emalex Biosciences Inc. | 2021-02-18 | Phase 1 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
